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Abstract: Hypericum perforatum L. has been used for 
centuries as a natural remedy for the treatment of many 
disorders. Neuropathic pain is a common side effect of 
oxaliplatin-based chemotherapy and often the cause of 
therapy discontinuation. Thanks to its anti-inflammatory 
and analgesic effects, the use of H. perforatum may be a 
novel therapeutic strategy for neuropathy. The aim of this 
paper was to evaluate the effect of H. perforatum hydro-
philic extract on an in vitro model of oxaliplatin-induced 
neurotoxicity. The antioxidant potential of extract was 
first evaluated in cell-free models by the thiobarbituric 
acid-reactive substances assay and nitro blue tetrazo-
lium oxidation test; the ability of H. perforatum extract 
to reduce oxaliplatin-induced caspase-3 activity in rat 
astrocytes and its potential interference with the cytotoxic 
effects of oxaliplatin in a colorectal cancer in vitro model 
(HT-29 cells) were also evaluated. The extract showed a 
significant antioxidant effect and was able to reduce cas-
pase-3 activity in rat astrocytes. Of note, the extract alone 
exerted a cytotoxic effect in HT-29 cells and did not reduce 
the cytotoxicity of oxaliplatin in HT-29 cells. These data 
suggest that H. perforatum could be used as a novel thera-
peutic strategy for counteracting chemotherapy-induced 
neuropathy.
Keywords: astrocyte; HT-29; Hypericum perforatum L.; 
neuropathy; oxaliplatin.
1  Introduction
Hypericum perforatum L. (St. John’s Wort) is a perennial 
flowering plant that has been used for centuries as a 
natural remedy for the treatment of a variety of disorders 
[1, 2]. Hypericum perforatum extracts contain several 
compounds with biological activity such as hypericin, 
pseudohypericin, flavonoids, oligomeric procyanidins 
and hyperforin [3]. In traditional medicine, this extract 
is used in patients with depression disorders [4]; it pos-
sesses antiviral and antibacterial activities and was 
reported to be beneficial in the management of hyper-
lipidemia and atherosclerosis [3]. Hypericum perforatum 
is well tolerated and does not cause major side effects, 
and it is considered a safe herbal therapeutic agent [5, 
6]. Neuropathic pain severely limits the quality of life 
and can be caused by a wide variety of injuries to periph-
eral nerves, including diabetes, traumatic injuries and 
treatment with chemotherapeutic drugs. Platinum ana-
logues, such as oxaliplatin, are one of the most common 
antineoplastic drugs successfully employed as first-line 
treatment for several solid and blood cancers [7]. The 
most common side effect of these drugs is chemother-
apy-induced neuropathy which often leads to reduction 
or discontinuation of therapy [7]. Oxaliplatin is able to 
induce neuropathic pain through several mechanisms 
including the modulation of Na+ channels [8], alteration 
in Ca2 + homeostasis [7], production of oxygen reactive 
species [9] and increase in caspase-mediated apoptosis 
[10]. Among those, oxidative stress is a key pathological 
feature of neuropathic pain [11–13]. Hyperforin, one of the 
major compounds found in H. perforatum, showed many 
pharmacological effects in vitro such as anti-inflamma-
tory and antioxidant [14]. Recently, H. perforatum extract 
was able to act on the onset and progression of neuro-
pathic pain by a protective role on Ca2 + entry through 
TRPM2 channels in rat dorsal root ganglia [15]. Galeotti 
and co-workers found that H. perforatum extract was 
able to relieve neuropathic pain in rat models (chronic 
constriction injury and oxaliplatin administration). 
They also demonstrated that hyperforin and hypericin 
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mediated its antihyperalgesic action through an opioid-
dependent pathway and the phosphorylation of PKC [16]. 
The aim of our paper was to characterize the content and 
the biological activities of a novel H. perforatum extract 
on a cellular model of oxaliplatin-induced neurotoxic-
ity. First, we evaluated H.  perforatum effects on oxidative 
stress and apoptosis in an in vitro model of neuropathic 
pain. The interaction between H. perforatum extract and 
oxaliplatin was also evaluated in an in vitro model of 
colorectal cancer.
2   Materials and methods
2.1   Hypericum perforatum hydrophilic 
fraction production
The production process is characterized by extracting 
the flowering tops of H. perforatum (cultivated and har-
vested by Aboca S.p.A., Sansepolcro, Italy). The dried top 
flowered herb undergoes extraction with ethanol 75% 
(v/v) (D/S 1 : 12). After 6–8 h, at 50 °C, the hydroalcoholic 
herb’s mixture was dropped for 1 h and filtered to remove 
the exhausted herb. The corresponding extract was con-
centrated under vacuum, till the alcohol concentration 
is reduced to 1%–3%. The concentration step provided a 
mixture where water insoluble compounds resulted as an 
amorphous precipitate. The solid was removed by means 
of a Decanter centrifuge and the resulting hydrophilic 
fraction underwent to freeze-drying for 72 h. The freeze-
dried fraction so obtained was stored until use, away from 
light and moisture.
2.2   Hyperforin and hypericin analysis
2.2.1   Sample preparation
The HPLC analysis in H. perforatum extract was performed 
according to the following method. Methanol (25 mL) was 
added to a sample of freeze-dried extract (0.5 g) and the 
resulting mixture was extracted protected from the light 
in an ultrasound bath at 35 °C for 30 min and then filtered 
in a volumetric flask. The filter was rinsed with further 
25 mL of methanol and extracted again in the same condi-
tions. After filtration the collected solutions were brought 
to 50 mL. The resulting solution was filtered on a cellulose 
acetate filter (0.45 μm) and used to perform HPLC analysis 
(Figure 1).
2.2.2   Hyperforin assay instrumental conditions
The measures were carried out by an Agilent 1100 Series 
LC/UV system consisting of a vacuum degasser, a quater-
nary pump, a Peltier autosampler thermostated at 20 °C, a 
Peltier column compartment thermostated at 20 °C and a 
UV detector. The column used was from Waters (Milford, 
MA; Spherisorb ODS2, 250  mm × 4.6  mm, 5 μm) and the 
elution was performed with H2O 0.2% phosphoric acid 
(solvent A), CH3CN (solvent B) and CH3OH (solvent C). The 
gradient program used was 0 min 85% A, 15% B, 0% C; 
10 min 70% A, 20% B, 10% C; 20 min 15% A, 75% B, 10% 
C in isocratic conditions till 45  min. The flow rate was 
1.2 mL/min. The detector UV/Vis was set at 270 nm. Rutin 
anhydrous (Extrasynthese), dissolved in methanol/water 
90/10, was used as a standard, and a response factor of 
1.75 was calculated against hyperforin. The linearity of the 
method was found between 0.0127 and 0.1  mg/mL. The 
working solutions were 0.1, 0.05, 0.025, 0.0127  mg/mL. 
The correlation found was r = 0.999998. Each solution was 
injected in triple; the CV was inferior to 1%.
2.2.3   Hypericin assay instrumental conditions
The measures were carried out by an Agilent 1100 Series 
LC/UV system consisting of a vacuum degasser, a quater-
nary pump, a Peltier autosampler thermostated at 20 °C, 
a Peltier column compartment thermostated at 20 °C, 
and a UV detector. The column used was from Waters 
(Milford, MA; Spherisorb ODS2, 250 mm × 4.6 mm, 5 μm) 
and the elution was performed with sodium dodecyl 
Figure 1: Hypericum perforatum extract’s antioxidant properties 
evaluated by biochemical assay in a cell-free model. NBT (nitro blue 
tetrazolium) levels oxidized by superoxide anion generated from the 
hypoxanthine-xanthine oxidase reaction. NBT levels were expressed 
as fluorescence arbitrary units. *p < 0.01 vs. control; ˆp < 0.01 vs. 
oxidized control.
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sulfate (SDS) 10  mM solution, pH 2.5 controlled with 
phosphoric acid (solvent A) and CH3CN (solvent B). The 
gradient program used was 0 min 25% A, 75% B; 15 min 
5% A 95% B. The flow rate was 1.2 mL/min. The detec-
tor UV/Vis was set at 590 nm. Hypericin (Sigma-Aldrich, 
Milan, Italy) was dissolved in methanol/pyridine 18/2. 
The linearity of the method was found between 0.06 
and 0.3 mg/mL. The working solutions were 0.061, 0.122, 
0.244  mg/mL. The correlation found was r = 0.999966. 
Each solution was injected three times; the CV was infe-
rior to 1%.
2.3   UPLC-MS/QToF fingerprint method
2.3.1   Sample preparation
MeOH 50% v/v (100 mL) was added to the sample (0.25 g). 
The resulting mixture was extracted in an ultrasonic bath at 
35 °C for 10 min and then centrifuged for 10 min at 4000 rpm. 
The pellet was suspended again in MeOH 50% v/v (100 mL) 
and extracted in the same conditions. After centrifuga-
tion the second extract was combined and the solution so 
obtained was transferred into a 200 mL flask. The sample 
was filtered on a 0.22 μm cellulose acetate syringe filter and 
then employed for the acquisition of the ESI-MS chromato-
graphic profile (negative and positive ion mode).
2.3.2   Instrumental conditions
The measurements were carried out by an MS/Q-ToF (Xevo 
G2XS, Waters) system equipped with an ESI source (Lock-
Spray, Waters). The system was coupled to an UPLC (H 
Class Aquity, Waters), equipped with a quaternary pump, 
an thermostated autosampler at 10 °C and a column com-
partment thermostated at 50 °C.
The parameters used were the following:
 – [ESI(–)]: polarity ES–, analyzer resolution mode, capil-
lary (kV) 2.5, sampling cone 40, source temperature (°C) 
150, source offset 80, desolvation temperature (°C) 500, 
cone gas flow (L/h) 50, desolvation gas flow (L/h) 1000.
 – [ESI(+)]: polarity ES+, analyzer resolution mode, cap-
illary (kV) 2.5, sampling cone 40, source temperature 
(°C) 150, source offset 80, desolvation temperature 
(°C) 500, cone gas flow (L/h) 50, desolvation gas flow 
(L/h) 1000.
The column used was an RP-C18 (Cortecs C18 Column, 
2.1  mm × 100  mm × 1.6 μm coupled to a VanGuard Pre-
Column 2.1 mm × 5 mm, Waters).
The elution was performed with H2O/HCOOH 125 mM 
(solvent A), MeOH (solvent B), H2O (solvent C) and MeOH/
HCOOH 125  mM (solvent D). The gradient program used 
was 0 min 20% A, 5% B, 75% C, 0% D; 1 min 20% A, 5% B, 
75% C, 0% D; 4 min 20% A, 45% B, 35% C, 0% D; 13 min 
20% A, 80% B, 0% C, 0% D; 14 min 20% A, 80% B, 0% C, 
0% D; 14.10 min 5% A, 80% B, 0% C, 15% D; 16 min 5% A, 
80% B, 0% C, 15% D; 16.10 min 20% A, 5% B, 80% C, 0% 
D; 18 min 20% A, 5% B, 75% C, 0% D. The flow rate was 
0.5 mL/min. The injection volume was 3 μL.
2.4   Lipid peroxidation (thiobarbituric acid-
reactive substances assay)
Thiobarbituric acid-reactive substances (TBARS) assay 
was assessed as an index of lipid peroxidation. The TBARS 
determination was carried out in rat brain homogenate 
obtained from brain tissue homogenized in PBS at the 
final concentration of 10% w/v. Then were added FeCl3 (20 
μM, Sigma-Aldrich, St. Louis, MO, USA) and ascorbic acid 
(100 μM, Sigma-Aldrich) to obtain the Fenton reaction 
both in the presence and in the absence of H. perforatum 
extract (50 μg/mL). At the end of incubation, the mixture 
was added to 4 mL reaction mixture consisting of 36 mM 
thiobarbituric acid (Sigma-Aldrich) solubilized in 10% 
CH3COOH, 0.2% SDS, and pH was adjusted to 4.0  with 
NaOH. The mixture was heated for 60 min at 100 °C and 
the reaction was stopped by placing the vials in an ice 
bath for 10 min. After centrifugation (at 1600 g at 4 °C for 
10 min) the absorbance of the supernatant was measured 
at 532 nm (PerkinElmer spectrometer).
2.5   Nitro blue tetrazolium oxidation test
The assay evaluated the nitro blue tetrazolium (NBT) 
superoxide anion-mediated oxidation and was performed 
as described by Ciuffi et  al. [17]. Briefly, the superox-
ide anion generated by the reaction between hypoxan-
thine (600  mM, Sigma-Aldrich) and xanthine oxidase 
(10  mU/mL, Sigma-Aldrich) caused the NBT (10  mM, 
Sigma-Aldrich) oxidation that was evaluated both in the 
presence and in the absence of H. perforatum extract 
(50 μg/mL). The reaction was appraised measuring the 
absorbance at 560 nm (PerkinElmer spectrometer).
2.6   Cell cultures
Rat astrocytes were extracted as described by McCa-
rthy and de Vellis previously [18], and human colorectal 
Brought to you by | Università degli Studi di Firenze
Authenticated
Download Date | 1/15/18 5:32 PM
222      Cinci et al.: Hypericum perforatum and oxaliplatin-induced neurotoxicity
adenocarcinoma cell HT-29 was a kind gift from Professor 
Enrico Mini (University of Florence).
2.7   Caspase-3 activity
Astrocyte and HT-29 cells were seeded in six-well plates 
(5 × 105/well) and grown until confluent. After 4 and 8 h 
of incubation with treatments (oxaliplatin 100 μM and 
H.   perforatum extract 5, 50, 250 μg/mL) the cells were 
scraped in 100 μL lysis buffer (200  mM Tris–HCl buffer, 
pH 7.5, containing 2 M NaCl, 20 mM EDTA and 0.2% Triton 
X-100). Fifty microliters of the supernatant was incubated 
with 25 μM fluorogenic peptide caspase substrate rhoda-
mine 110 bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspar-
tic acid amide) (molecular probes) at 25 °C for 30 min. The 
amount of cleaved substrate in each sample was measured 
in a 96-well plate fluorescence spectrometer (PerkinElmer; 
excitation at 496 nm and emission at 520 nm).
3   Results
3.1   Hypericum perforatum hydrophilic 
fraction characterization
The production process of the fraction used for this study 
is characterized by the extraction of the dried flowered 
aerial part of H. perforatum by means of ethanol 75%, a 
solvent known to extract most of the metabolite produced 
from medicinal plants, comprising some terpenes and free 
fatty acids. During the concentration step under vacuum, 
required to prepare the concentrate to be subject to freeze-
drying, a precipitate was formed. This feature indicated 
that the starting hydroalcoholic extract 75% contained a 
mixture of compounds with different solubility character-
istics, molecular species present being more polar, soluble 
in water, and less polar, soluble in ethanol 75% but insolu-
ble in water. So, before freeze-drying, the concentrate was 
treated by centrifugation affording two different fractions: 
the first one, the surnatant, is composed of compounds 
completely soluble in water (hydrophilic fraction), and 
a second “less polar” fraction, the pellet, characterized 
by compounds soluble in ethanol 75% but insoluble 
in water. To perform a rational characterization of the 
“hydrophilic fraction”, the presence of the most specific 
markers of HP, hyperforins and hypericins, was analyzed. 
The hydrophilic fraction obtained as reported before has 
a hyperforin content of 0.248% (as sum of hyperforin 
and adhyperforin, calculated as hyperforin) and 0.154% 
of total hypericins (as sum of hypericin and pseudohy-
pericin, calculated as hypericin). This result must be cor-
related with the results of the other fraction separated 
during the process. The percentage of hypericins was 
similar, but hyperforins reach values from 50- to 100-fold 
higher, confirming that the production process used is 
convenient to obtain an original fraction of HP depleted in 
hyperforin content. Comparing this result with a classical 
HP freeze-dried extract, we can observe again a difference 
on the hyperforin content, as generally the hydrophilic 
fraction has one fifth of hyperforin content. The hydro-
philic fraction was further characterized acquiring its 
chromatographic fingerprint by means of an LC-MS/Q-
ToF. Several other not quantified compounds were identi-
fied in H. perforatum extract, as reported in Table 1. The 
hydrophilic fraction contains hyperforins 0.248% (sum of 
hyperforin and adhyperforin, calculated as hyperforin) 
and 0.154% of total hypericins (sum of hypericin and 
pseudohypericin, calculated as hypericin). The fraction 
was further characterized. A chromatographic fingerprint 
analysis by means of an LC-MS/Q-ToF was performed and 
the characteristic compounds of H. perforatum, reported 
in Table 1, were detected. A chromatographic profile of 
H. perforatum hydrophilic fraction is reported in supple-
mentary materials.
3.2   Hypericum perforatum extract’s antioxi-
dant properties
Hypericum perforatum whole extract showed antioxidant 
activity both in cellular and cell-free models. In a cell-
free model, Hypericum extract was able to reduce the 
oxidized NBT (mediated by superoxide anion from the 
hypoxanthine-xanthine oxidase reaction) (Figure 1), and 
in a tissue-derived model, the TBARS content (indicator 
of lipid injury mediated by oxygen reactive species gen-
erated by the Fenton reaction) was reduced by the treat-
ment with Hypericum extract (Figure 2). In a primary 
culture of rat astrocytes, the treatment with oxaliplatin 
(100 μM for 4 h) induced O2−˙ production which was sig-
nificantly reduced by the co-administration of Hypericum 
extract (Figure 3).
3.3   Effects of H. perforatum extract on 
oxaliplatin-induced apoptosis in primary 
rat astrocytes
In primary rat astrocytes, oxaliplatin induced a marked 
increase of caspase-3 activity both after 4 and 8  h of 
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treatment. Hypericum perforatum extract, at all concen-
trations tested (5, 50, 250 μg/mL), was able to reduce the 
increased caspase-3 activity only after 4 h, whereas after 
8 h, only the highest concentration (250 μg/mL) had a sig-
nificant effect (Figure 4).
3.4   Effects of H. perforatum extract alone 
or in combination with oxaliplatin on 
apoptosis in HT-29 colon cancer cells
In oxaliplatin-treated HCT-29 colon cancer cells, H. perfo-
ratum extract did not interfere with the cytotoxic activity 
of oxaliplatin at both 4 and 8 h of treatment. Of note, the 
extract alone was able to exert an unusual effect induc-
ing a proapoptotic response similar to that produced by 
oxaliplatin after 4 h of treatment. After 8 h this effect was 
lost (Figure 5).
4   Discussion
Neuropathic pain is one of the most common side effects 
of platinum-based chemotherapy, significantly affects 
Table 1: Compound identified on Hypericum perforatum hydrophilic fraction.
Compound   RT  Ion 
polarity
  Adduct 
ion
  Experimental 
mass (scan base 
peak mass), m/z
  MSE ions  Theoretical 
neutral 
mass, m/z
  Delta, 
ppm
Vanillic acid   2.15  Negative   [M-H] −   167.0322  108.0189  168.0422  16.5
Neochlorogenic acid   2.40  Negative   [M-H] −   353.0857  191.0581  354.0951  6.3
Chlorogenic acid   3.18  Negative   [M-H] −   353.0857  191.0553  354.0951  6.3
Cryptochlorogenic acid   3.32  Negative   [M-H] −   353.0857  173.0462
191.0553
  354.0951  6.3
Luteolin-7-O-glucuronide   4.51  Negative   [M-H] −   461.0739  285.0409  462.0798  2.8
Hyperoside   4.60  Negative   [M-H] −   463.0938  300.0290  464.0954  12.0
Quercetin 3-O-glucoside-6″-acetate  4.71  Negative   [M-H] −   505.0986  300.0290  506.1060  0.4
Orientin/homoorientin   4.81  Negative   [M-H] −   447.0932  327.0497  448.1006  0.5
Rutin   4.87  Negative   [M-H] −   609.1471  300.0254  610.1534  1.5
Quercitrin   4.92  Negative   [M-H] −   447.0975  151.0036  448.1006  9.2
Quercetin   5.44  Negative   [M-H] −   301.0368  151.0036  302.0426  4.5
Eupatorin-5-methyl ether   7.15  Negative   [M-H] −   357.0976  342.0714  358.1052  1.0
I3,II8-Biapigenin/amentoflavone   8.08  Negative   [M-H] −   537.0821  375.0508  538.0900  1.3
Figure 2: Hypericum perforatum extract’s antioxidant proper-
ties in a tissue-derived model. TBARS (thiobarbituric acid reactive 
substances) levels obtained by the Fenton reaction. Values were 
expressed as percentage with respect to control. *p < 0.01 vs. 
control; ˆp < 0.01 vs. oxidized control.
Figure 3: Antioxidant properties of Hypericum perforatum extract 
in a primary culture of rat astrocytes. The production of O2˙− was 
evaluated after 4 h of 100 μM oxaliplatin treatment both in the 
absence and in the presence of 50 μg/mL Hypericum perforatum 
extract. Values are expressed as mean ± SEM of three independ-
ent experiments performed on three different biological samples 
for each treatment. *p < 0.01 vs. untreated control and ˆp < 0.01 vs. 
oxaliplatin treatment.
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quality of life and is often the cause of therapy discon-
tinuation. The identification of novel supplementary 
therapeutic strategies able to counteract the onset and 
the progression of chemotherapy-induced neuropathy 
is therefore of paramount importance. The mechanisms 
behind the onset of chemotherapy-induced neuropathy 
are far to be fully clarified, but a key role of oxidative stress 
has been suggested. Di Cesare Mannelli and co-workers 
described the pivotal role of oxidative stress in a rat model 
of painful oxaliplatin-induced neuropathy. In the plasma 
of oxaliplatin-treated rats, the increases in carbonylated 
protein and thiobarbituric acid reactive substances were 
the index of the resultant protein oxidation and lipoper-
oxidation, respectively. The same pattern of oxidation was 
also found in the sciatic nerve and in the spinal cord [11]. 
The characterization of our H. perforatum extract revealed 
the presence of several compounds with antioxidant prop-
erties such as phenolic acids, and its ability to reduce oxi-
dative stress was demonstrated in two cell-free models. 
Our extract reduced both the presence of oxygen reactive 
species and the oxidative stress-induced damage to bio-
logical molecules. Several lines of evidence suggest a rela-
tionship between oxaliplatin-induced neurotoxicity and 
oxidative stress [9]. Other data supported this observation, 
but the relationship between the increased generation of 
ROS after platinum treatment and other mechanisms of 
oxaliplatin neurotoxicity remains poorly understood [7]. 
Data from Joseph et  al. suggest that oxaliplatin-induced 
neuropathy is mediated by IB4 nociceptors and induces 
oxidative stress [19]. Zheng and collaborators reported 
that oxaliplatin is able to produce deleterious effects on 
axonal mitochondria leading to electron transport chain 
disruption and cellular energy failure in DRG neurons. 
The mitochondrial damage could be the starting point for 
increased ROS generation [20]. Thanks to its antioxidant 
properties, H. perforatum extract seems to be a promis-
ing candidate as a therapeutic agent against oxidative 
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Figure 4: Caspase activity in astrocytes culture. Cells were treated 
with oxaliplatin 100 μM for 4 h (panel A) and 8 h (panel B) both 
in the absence and presence of 5, 50, 250 μg/mL Hypericum 
perforatum extract. Values, expressed as mean ± SEM from four 
independent experiments, were reported as percentage compared 
with control. *p < 0.01 vs. control. ˆp < 0.01 vs. control treated with 
oxaliplatin.
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Figure 5: Caspase-3 activity evaluated on HT-29 cells. The figure 
shows the effect of oxaliplatin administration on caspase-3 activity 
evaluated both in the presence and in the absence of Hypericum 
perforatum extract after 4 h (panel A) and 8 h (panel B). The values 
are expressed in percentage compared with control and reported 
as the mean ± SEM of four independent experiments, performed on 
three different biological samples for each treatment. *p < 0.01 vs. 
control. ˆp < 0.01 vs. control treated with oxaliplatin.
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stress-induced neuropathy. Hypericum perforatum extract 
showed protective effects against H2O2-induced apoptosis 
in PC12 cells [21] and exerted local and systemic protective 
effects in ischemia reperfusion injury in the rat liver [22].
Ta and co-workers demonstrated the involvement 
of caspases in oxaliplatin-induced neuropathy [10], 
whereas prolonged exposure to oxaliplatin induced the 
activation of MAP-kinase proteins p38 and ERK1/2, which 
in turn mediate apoptosis in rat dorsal root ganglia [23]. 
Conversely, oxaliplatin treatment was able to downregu-
late protective JNK/Sapk [24]. Our data highlight that 
H. perforatum extract exerts a protective effect on apopto-
sis induced by oxaliplatin in rat astrocytes (model of glial 
cells as the target of chemotherapy-induced damage), and 
this effect was evident at all concentrations tested after 
4 h, whereas only the higher one maintained its efficacy 
after 8 h. We also evaluated the possible interference of 
H. perforatum extract on the cytotoxicity of oxaliplatin. To 
evaluate this aspect, the antiapoptotic effects of H. perfo-
ratum extract were assessed also on an in vitro model of 
colorectal cancer (HT-29 cells). In this model H. perforatum 
showed no ability to reduce caspase-3 activity induced by 
oxaliplatin treatment both after 4 and 8 h, suggesting that 
H. perforatum does not interfere with the cytotoxic activ-
ity of oxaliplatin against cancer cells and therefore it may 
be used as adjuvant therapy to counteract chemotherapy-
induced neuropathy. We are also among the first to report 
that H. perforatum extract exerts a proapoptotic effects 
similar to that exerted by oxaliplatin in HT-29 cells after 
4 h of treatment. These peculiar results are in line with 
those reported in previous studies showing that the oxali-
platin apoptosis-inducing mechanism is preferentially 
mediated in astrocytes by the intrinsic pathway and by 
the extrinsic pathway in the colon cancer cell HT-29 [25]. 
The intrinsic pathway is promoted by a mitochondrial 
alteration characterized by membrane potential changes, 
release of cytochrome C and redox unbalance [25]. Several 
studies showed that oxaliplatin promotes the release of 
cytochrome C from mitochondria to the cytosol in normal 
glial cells and increases of swollen and vacuolated mito-
chondria in peripheral nerve axons of neuropathic rats 
[20, 26]. Caspase-8 is one of the principal initiators of 
the extrinsic process and directly activates the effector 
caspase-3. Zanardelli and co-workers confirmed the acti-
vation of the extrinsic pathway in HT-29 cells by oxalipl-
atin treatment and demonstrated a lesser sensitivity of the 
mitochondria functionality against oxaliplatin toxicity in 
HT-29 in comparison to astrocytes [25]. Hypericum perfo-
ratum might also act differently in two different apoptotic 
pathways causing an apoptotic impulse in HT-29 cells and 
a protective effect in astrocytes. In conclusion, our data 
suggest the use of H. perforatum extract as a novel strat-
egy for chemotherapy-induced neuropathy.
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